Sarepta Therapeutics
Healthcare & Life Sci
Company overview
Sarepta Therapeutics is a biotechnology company based in Cambridge, United States. It develops gene therapy, RNA-based therapies and siRNA treatments for rare genetic diseases, especially muscular dystrophies.
Sarepta started in 1980 in Corvallis, Oregon, as Antivirals Inc. It was renamed AVI BioPharma in 2002 and became Sarepta Therapeutics in 2012. The FDA approved its drug eteplirsen in 2016 and its gene therapy ELEVIDYS in 2023. Sarepta is a public company traded on Nasdaq as SRPT, with $1.145 billion in revenue and 1,314 employees in 2023. That matters: two FDA-approved therapies give Sarepta products it can sell now, not just drugs still in testing. Historically, the median salary is ~$180,900. Sarepta Therapeutics is a top-tier H-1B sponsor.
- Industry
- Healthcare & Life Sci
- Headquarters
- Cambridge, United States